Document Detail

Drug evaluation of clevidipine for acute hypertension.
MedLine Citation:
PMID:  18778189     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Clevidipine is an investigational agent undergoing late-stage clinical development to evaluate its potential as a novel short-acting intravenous agent for treating acute hypertension, either in hypertensive emergencies encountered in the emergency department and intensive care units, or in the perioperative period. METHOD: Clevidipine has been evaluated in four Phase I studies, nine Phase II studies and six Phase III clinical studies. The patient populations studied include healthy volunteers, patients with essential hypertension, patients undergoing cardiac surgery, and patients presenting to the emergency department with hypertensive emergencies. Studies providing comparative data of clevidipine versus nitroglycerin, nicardipine or sodium nitroprusside are also available. OBJECTIVE: This article reviews the results of clinical studies evaluating the pharmacological properties, clinical effects and safety profiles of clevidipine in various patient populations. RESULTS/CONCLUSION: Clevidipine is an effective agent for reducing acute elevation in blood pressure in various settings, including hypertensive emergencies and perioperative hypertension with a good safety profile.
Ika Noviawaty; Guven Uzun; Adnan I Qureshi
Related Documents :
6110039 - Immunological changes in patients with previous malignant essential hypertension.
11133249 - Obstructive sleep apnea and hypertension: are peripheral chemoreceptors involved?
16037729 - Modeling adherence to therapeutic regimens in patients with hypertension.
569669 - Idiopathic hypertrophic subaortic stenosis as observed in a large community hospital: r...
16647769 - Apnea/hypopnea index and benzodiazepine use in patients with arterial hypertension and ...
8576899 - Increased thickness of the carotid artery in patients with essential hypertension and m...
21991089 - Marjolin's ulcers on the thigh two years after burn.
646909 - Height and weight gain after total correction of fallot's tetralogy.
20065249 - Preserved brain adaptive properties in patients with benign multiple sclerosis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  9     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-09-09     Completed Date:  2008-12-29     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2519-29     Citation Subset:  IM    
University of Minnesota, Zeenat Qureshi Stroke Research Center, Department of Neurology, MMC 295, 420 Delaware St S.E., Minneapolis, MN 55455, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Calcium Channel Blockers / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Clinical Trials as Topic
Hypertension / drug therapy*
Pyridines / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Pyridines; 0/clevidipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New therapeutic option for thromboembolism--dabigatran etexilate.
Next Document:  Valacyclovir for the treatment of Bell's palsy.